Kaiser adds to payer ire over Sovaldi price
Kaiser Permanente, the big HMO, is swallowing the cost of Gilead's hepatitis C treatment Sovaldi, but is angry about the $84,000 cost.
“It's an outrageous price for a therapy that has huge public health implications,” associate director of the Permanente Medical Group Sharon Levine tells Reuters. Levine says that the medication will be what Reuters described as a “material portion of its drug budget,” even with a discounted rate.
Gilead has claimed that Sovaldi's high price trades short-term financial burden for long-term savings by helping patients avoid later expenses, such as those associated with liver failure.